Infusion Pumps Total Product Life Cycle – Guidance for Industry and FDA Staff (PDF

%PDF-1.7% 4373 0 objstream hÞ¬oo]Ǎ}`ahbAI# /p#~%3ײ @C;Ù!99zHz~Z0 _AA4o%^~PRC`j2{sCo6n380Æ´ÔžnOÙžw9؟٫iVb5[J95[Q{Úš-Ó– -ـƯوBIJ7tkߍIwl6 ](M VÔžMj{.O{{SLb iiIk7~5ß°O7-2i2|N],Ji”?zj/8l51fT’!W]l:g3/s!_vq6q8S90kIÚ˜d+5knOoÌžÔ¤dZ5s4i”Ku#u+Q5͘pf7Ic]8uC7Å’:],feX̬kras6;9Ù˜NGsqC+fÙ¦)nHxnưm[67oh:nYSuinbÓµÕªoɲTrU4SIJvo5Q[}52Γmv^hKnLFe3+f}kgWl}Ó›MFu~.]gV]2F}JJrOD863;U;{no[fB!uf_7u{k{.wVn󌭋D=75’Zn*%ߍoÞ…kF4_X᫯/j[i~y :Ó§ÇŸSvOÞŸc5eÓŸÏžsU쏗W~k|/Ù‹7/_]vy}{W8Õ¯=onxOW߿̪?{Õ§”ӐOCwç¶“ì·‹5CÉ‹F4Vw΍m{mNVm=m0_=dxw?/gÓ§qvnÏ¥)sG1=ч)=6l*o!MZrÛ²]Û®k˃Cnd;MeÓµRgYlX׍Y5t,zB)Y)]_~|; {wf}WH%Nk^-_`Os8D2b)lƶˬ݈wvqKbODßܣON1”S{*N!{fA[fs7܍`F0w=4|*]r’w=I9OyG^}R~,GϏ5vFc3/8.,jߎZJf ,祱قʣlÆ |RL4F^{ne6۹ǏQ}OI{T’_}I’q[x0:T0mvÓ½]7AH%Ô­nglmÍ”26zoOf9?fw(QNQ#vcÙ·#Й4tCg9hxca9[9’Lu;K!;K%;K#;K’; ;$ ;lGVTtz]a}u1jYÑ“c’pÞ¿%EmQb[Tg3xT]Í•zb|NSq}1.:O;E’Lj߾5Õ¯7yFjp(_L{b/^8?{ysÛ³?f#|Ï¿__뛫Wnn;Μ77]~Ýž6Am7fz#nUX3!sCиx!Z:c/csh)w6=C7ɽf10P4k??87f~]7/_x2O}^vy囫W__~siÏ·ad$ScuKʐCnß¾}{{RÒ“ene|2bUybIrb̧}ÝŸX=ln^v~|Xb6yym%|ebSkzYri?zå¶„}ß›voo{4Ê–l_{0m#+6_EUqJeQ ‘6Va[LOOOOabxZ鎁W|çS|GZRZqWTwK4Xba Q0jaa-ltz Aw|cOl|peg}}2 MKQ”:]H(#:HoPM0P`(0܁SXF^Dh”1#1#ÄŒ3˃1#ÄŒr) /(iBOH “(Qp?QpPpP2mP_腍^ eߦ[email protected])e,(#2%cdYm`#ÏŒJ/$egAGbFedh’Ld`eMdMeOƹeƌʑ8 X|](BWL|6 LØ…L-%lGÈ”}Ke_*nJ1;e;*IÙŽ`bUQÙ©NU,R1DSO6e*Ö¦Xbm)Ö¦XVQSI(bRÊ·Lq*UTw!4+$TސʂHmdAa|?g!I@azl-3e@2NfÉ«1SE :H’d@,hWÂ,B4#(^,@7Rß!bfK(,+JlzJ)6J’V)zH N7;t6b5P;,Y5Abb%Z}gÍ…u jt);};zeĆ02Cd8Vн0VabA+|*|*+W77Ó˜Oc;[m H| ɈA/1hZN0Vz ߁Xb6uan ht8ww8wÆ€!i88dx1k6Ot0.0v.t4v4#4″ZwTgDXzFtg?u+O1/4l1c3XIJL`X@G=@#a.{`,kqVplHW[XΤ!riÈ¥!@Ad5SCv”/kCԐfgoGtG

Emergency Use Authorizations (November 26 – Amended RealStar® Ebolavirus RT

2014 Ebola Virus Emergency Use Authorization 2013 Coronavirus Emergency Use Authorization (Potential Emergency) 2013 H7N9 Influenza Emergency Use Authorization (Potential Emergency) Historical Information, Termination of Declaration Letters and Additional Information 2013 Coronavirus Emergency Use Authorization (Potential Emergency) On May 29, 2013 Secretary Kathleen Sebelius determined that Middle East respiratory syndrome coronavirus (MERS-CoV) poses a significant…

UPDATED Laparoscopic Uterine Power Morcellation in Hysterectomy and Myomectomy: FDA Safety Communication

The following information updates our April 17, 2014 communication. Date Issued: Nov. 24, 2014 Audience: Health Care Providers Medical Professional Associations Cancer Advocacy Organizations Health Care Facilities/Hospitals Women with Symptomatic Uterine Fibroids who are Considering Surgical Options Manufacturers of Devices used for Minimally Invasive Surgeries Medical Specialties: Pathology, Internal Medicine, Nursing, Obstetrics/Gynecology, Oncology, Obstetrics/Gynecological Surgery;…

FDA Voice Blog: China Journal: strengthening relationships to protect public health

By: Margaret A. Hamburg, M.D. I am just about to wrap up a jam-packed five-day visit to China, a fascinating country with a dramatically growing economy and with an increasingly significant impact on the products that Americans consume. Indeed, a key reason for my trip is the important and growing collaboration between FDA and our…